Mike Kratky
Stock Analyst at Leerink Partners
(3.29)
# 1,020
Out of 5,149 analysts
41
Total ratings
41.67%
Success rate
24.62%
Average return
Main Sectors:
Stocks Rated by Mike Kratky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRCT PROCEPT BioRobotics | Maintains: Outperform | $55 → $30 | $26.26 | +14.24% | 2 | Feb 26, 2026 | |
| PODD Insulet | Maintains: Outperform | $386 → $360 | $241.84 | +48.86% | 2 | Feb 19, 2026 | |
| TXG 10x Genomics | Maintains: Market Perform | $22 → $20 | $22.62 | -11.58% | 5 | Jan 27, 2026 | |
| PEN Penumbra | Downgrades: Market Perform | $374 | $340.16 | +9.95% | 2 | Jan 16, 2026 | |
| BSX Boston Scientific | Maintains: Outperform | $127 → $128 | $73.85 | +73.32% | 2 | Oct 1, 2025 | |
| INSP Inspire Medical Systems | Maintains: Market Perform | $116 → $97 | $65.80 | +47.42% | 7 | Aug 15, 2025 | |
| MDT Medtronic | Initiates: Outperform | $110 | $96.71 | +13.74% | 1 | Jun 16, 2025 | |
| BBNX Beta Bionics | Initiates: Outperform | $28 | $11.57 | +142.01% | 1 | Feb 24, 2025 | |
| DXCM DexCom | Maintains: Outperform | $90 → $87 | $73.08 | +19.05% | 2 | Oct 25, 2024 | |
| TNDM Tandem Diabetes Care | Upgrades: Outperform | $34 → $45 | $23.74 | +89.55% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $13.83 | +59.07% | 1 | Jan 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $34.39 | +22.13% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $342 | $497.42 | -31.25% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $75 | $85.28 | -12.05% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $29.83 | -69.83% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $325 → $50 | $28.08 | +78.06% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $45 | $1.25 | +3,500.00% | 2 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $145 → $315 | $425.85 | -26.03% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $26 → $31 | $86.35 | -64.10% | 2 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $26.71 | -47.59% | 1 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $40 | $29.32 | +36.43% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $392 → $384 | $58.01 | +561.95% | 1 | Aug 11, 2022 |
PROCEPT BioRobotics
Feb 26, 2026
Maintains: Outperform
Price Target: $55 → $30
Current: $26.26
Upside: +14.24%
Insulet
Feb 19, 2026
Maintains: Outperform
Price Target: $386 → $360
Current: $241.84
Upside: +48.86%
10x Genomics
Jan 27, 2026
Maintains: Market Perform
Price Target: $22 → $20
Current: $22.62
Upside: -11.58%
Penumbra
Jan 16, 2026
Downgrades: Market Perform
Price Target: $374
Current: $340.16
Upside: +9.95%
Boston Scientific
Oct 1, 2025
Maintains: Outperform
Price Target: $127 → $128
Current: $73.85
Upside: +73.32%
Inspire Medical Systems
Aug 15, 2025
Maintains: Market Perform
Price Target: $116 → $97
Current: $65.80
Upside: +47.42%
Medtronic
Jun 16, 2025
Initiates: Outperform
Price Target: $110
Current: $96.71
Upside: +13.74%
Beta Bionics
Feb 24, 2025
Initiates: Outperform
Price Target: $28
Current: $11.57
Upside: +142.01%
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $90 → $87
Current: $73.08
Upside: +19.05%
Tandem Diabetes Care
Apr 25, 2024
Upgrades: Outperform
Price Target: $34 → $45
Current: $23.74
Upside: +89.55%
Jan 30, 2024
Initiates: Outperform
Price Target: $22
Current: $13.83
Upside: +59.07%
Oct 16, 2023
Initiates: Outperform
Price Target: $42
Current: $34.39
Upside: +22.13%
Oct 16, 2023
Initiates: Outperform
Price Target: $342
Current: $497.42
Upside: -31.25%
Oct 16, 2023
Initiates: Market Perform
Price Target: $75
Current: $85.28
Upside: -12.05%
Oct 16, 2023
Initiates: Outperform
Price Target: $9
Current: $29.83
Upside: -69.83%
Aug 15, 2023
Downgrades: Market Perform
Price Target: $325 → $50
Current: $28.08
Upside: +78.06%
Jan 24, 2023
Maintains: Outperform
Price Target: $33 → $45
Current: $1.25
Upside: +3,500.00%
Dec 20, 2022
Maintains: Outperform
Price Target: $145 → $315
Current: $425.85
Upside: -26.03%
Dec 15, 2022
Maintains: Market Perform
Price Target: $26 → $31
Current: $86.35
Upside: -64.10%
Nov 4, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $26.71
Upside: -47.59%
Aug 15, 2022
Maintains: Outperform
Price Target: $32 → $40
Current: $29.32
Upside: +36.43%
Aug 11, 2022
Maintains: Outperform
Price Target: $392 → $384
Current: $58.01
Upside: +561.95%